报价延迟最少15分钟:2026/10/24 08:32 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
42.53 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
0.48/0.68
|
|
企业价值
2.28B
|
| 资产负债 |
|
每股账面净值
7.23
|
| 现金流量 |
|
现金流量率
0.03
|
| 损益表 |
|
收益
--
|
|
每股收益
3.62
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| Vericel Corp is a fully integrated commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions. |
